アブストラクト
| Title | 薬剤性の浮腫 |
|---|---|
| Subtitle | 特集 身体・検査所見を体液評価に活かす 浮腫と脱水の薬物治療 各論 |
| Authors | 植松卓也, 中塚真衣子 |
| Authors (kana) | |
| Organization | 順天堂大学医学部附属順天堂医院薬剤部 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 13 |
| Page | 2701-2707 |
| Year/Month | 2022 / 10 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●浮腫の発生機序には, 多種多様な要因が関与するが, 多くの薬剤もその要因となりうる. ●薬剤性末梢性浮腫は, 4つの主要なメカニズムにより, 血管透過性浮腫, リンパ性浮腫, 血管拡張性浮腫, 腎性浮腫に分けられる. ●末梢性以外にも血管性浮腫, RS3PE症候群があり, 特に血管性浮腫は重篤化する場合もあるため注意が必要である. ●ハイリスク患者やリスク薬を服用する患者には, 薬剤性浮腫の発症予防も考慮しながら慎重な事前評価と継続的なモニタリングが重要である. ●薬剤性浮腫に対する治療の第一原則は, 被疑薬の中止または減量であるが, 類縁薬への変更も検討すべきである. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Siddall EC, et al : The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int, 82 : 635-642 2012
- 2) Cho S, et al : Peripheral edema. Am J Med, 113 : 580-586, 2002
- 3) Largeau B, et al : Drug-induced peripheral oedema : An aetiology-based review. Br J Clin Pharmacol, 87 : 3043-3055, 2021
- 4) 安田 尚, 他 : 薬剤性浮腫. Fluid Management Renaissance, 2 : 61-68, 2012
- 5) Hinchcliff ME, et al : Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate. Rheumatology, 55 : 1916-1918, 2016
残りの31件を表示する
- 6) Jeong GH, et al : Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients : A systematic review and meta-analysis. J Clin Med, 8 : 143, 2019
- 7) Siddall E, et al : Capillary leak syndrome : etiologies, pathophysiology, and management. Kidney Int, 92 : 37-46, 2017
- 8) Guilhot F : Indications for imatinib mesylate therapy and clinical management. Oncologist, 9 : 271-281, 2004
- 9) Rashid-Farokhi F, et al : Lymphedema of the transplanted kidney and abdominal Wall with ipsilateral pleural effusion following kidney biopsy in a patient treated with sirolimus : A case report and review of the literature. Am J Case Rep, 18 : 1370-1376, 2017
- 10) Aboujaoude, W, et al : Lymphedema associated with sirolimus in renal transplant recipients. Transplantation, 77 : 1094-1096, 2004
- 11) Mahe E, et al : Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation, 79 : 476-482, 2005
- 12) Messerli FH : Vasodilatory edema : a common side effect of antihypertensive therapy. Curr Cardiol Rep, 4 : 479-482, 2002
- 13) Freeman R, et al : Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy : findings from seven randomized, controlled trials across a range of doses. Diabetes Care, 31 : 1448-1454, 2008
- 14) Gilron I, et al : Gabapentin and pregabalin for the treatment of neuropathic pain : A review of laboratory and clinical evidence. Pain Research and Management, 11 : 16A-29A, 2006
- 15) Largeau B, et al : Gabapentinoid-induced peripheral edema and acute heart failure : A translational study combining pharmacovigilance data and in vitro animal experiments. Biomedicine & Pharmacotherapy, 149 : 112807, 2022
- 16) Gallagher R, et al : Peripheral edema with pregabalin. Cmaj, 185 : E506, 2013
- 17) Kanbay M, et al : Gabapentin induced edema in a geriatric patient. Clin Neuropharmacol, 29 : 186, 2006
- 18) Wustmann T, et al : Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry, 42 : 75-76, 2009
- 19) Messerli FH : Vasodilatory edema : a common side effect of antihypertensive therapy. Am J Hypertens, 14 : 978-979, 2001
- 20) Guzelkucuk U, et al : Reversible post-pregabalin peripheral edema in a spinal cord injury patient. Spinal Cord, 50 : 472-473, 2012
- 21) Kimura Y, et al : Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain : A multi-center, prospective, single-arm, open-label study. Pain Ther, 10 : 711-727, 2021
- 22) Vercauteren M, et al : Endothelin ET(A) receptor blockade, by activating ET(B) receptors, increases vascular perme-ability and induces exaggerated fluid retention. J Pharmacol Exp Ther, 361 : 322-333, 2017
- 23) Wei A, et al : Clinical adverse effects of endothelin receptor antagonists : Insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc, 5 : e003896, 2016
- 24) 中村倫太郎, 他 : 長期間Angiotensin Converting Enzyme阻害薬服用中に発症した致死的血管性浮腫の1例. 産業医科大学雑誌, 38 : 61-64, 2016
- 25) 厚生労働省 : 血管性浮腫(非ステロイド性抗炎症薬によらないもの). 重篤副作用疾患別対応マニュアル(令和元年9月改定)(https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1h05_r01.pdf)
- 26) Cicardi M, et al : Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract, 6 : 1132-1141, 2018
- 27) Stone C, et al : Angiotensin-converting enzyme inhibitor and other drug-associated angioedema. Immunol Allergy Clin North Am, 37 : 483-495, 2017
- 28) Irons BK, et al : Valsartan-induced angioedema. Ann Pharmacother, 37 : 1024-1027, 2003
- 29) McCarty DJ, et al : Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA, 254 : 2763-2767, 1985
- 30) Paira S, et al : Remitting seronegative symmetrical synovitis with pitting oedema : A study of 12 cases. Clinical Rheumatology, 21 : 146-149, 2002
- 31) Yamauchi K, et al : RS3PE in association with dipeptidyl peptidase-4 inhibitor : report of two cases. Diabetes Care, 35 : e7, 2012
- 32) 日高尚子, 他 : DPP-4阻害薬によるRS3PE症候群の発症・増悪を疑われた6例の検討. 糖尿病, 2019
- 33) Yoshioka Y, et al : THE ASSOCIATION OF THE EARLY ONSET OF REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING OEDEMA(RS3PE) SYNDROME WITH DIPEPTIDYL PEPTIDASE-4(DPP4) INHIBITOR. Annals of the Rheumatic Diseases, 77 : 1686-1686, 2018
- 34) 三田智也, 他 : DPP-4阻害薬, 最近の話題 ; 血糖以外の多面的作用. 糖尿病, 56 : 741-743, 2013
- 35) Gauci ML, et al : Remitting seronegative symmetrical synovitis with pitting edema(RS3PE) syndrome induced by nivolumab. Semin Arthritis Rheum, 47 : 281-287, 2017
- 36) Arima K, et al : RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis, 64 : 1653-1655, 2005
